Patient characteristics
| All patients (n=16) | Chemo+TIL (n=13) | Chemo+TIL+IFNa (n=3) | |
| Age | |||
| Median age and range (year) | 61 (29–77) | 62 (29–77) | 58 (53–73) |
| WHO status; n (%) | |||
| 0 | 6 (38) | 6 (46) | 0 (0) |
| 1 | 10 (62) | 7 (54) | 3 (100) |
| 2 | 0 (0) | 0 (0) | 0 (0) |
| Tumor type | |||
| HGSOC | 15 (94) | 12 (92) | 3 (100) |
| LGMOC | 1 (6) | 1 (8) | 0 (0) |
| Platinum sensitivity | |||
| >6 and <12 months | 6 (38) | 5 (38) | 1 (33) |
| >12 months | 10 (62) | 8 (62) | 2 (67) |
| Mutation status; n (%) | |||
| BRCA mutation | 2 (13) | 2 (15) | 0 (0) |
| HR status; n (%) | |||
| ER− and PrR− | 4 (25) | 3 (23) | 1 (33) |
| ER+ or PrR+ | 7 (44) | 6 (46) | 1 (33) |
| Unknown | 5 (31) | 4 (31) | 1 (33) |
| Previous lines of chemotherapy; n (%) | |||
| 1 | 12 (75) | 10 (77) | 2 (67) |
| 2 | 3 (19) | 2 (15) | 1 (33) |
| >3 | 1 (6) | 1 (8) | 0 (0) |
| Other previous treatments; n (%) | |||
| Bevacizumab | 2 (13) | 1 (8) | 1 (33) |
| Endocrine therapy | 2 (13) | 1 (8) | 1 (33) |
| PARPi | 2 (13) | 1 (8) | 1 (33) |
ER, estrogen receptor; HGSOC, high grade serous ovarian cancer; HR, hormone receptor; LGMOC, low-grade mucinous ovarian cancer; PrR, progesterone receptor.